AYTU: EXXUA launch drove $6.6M in revenue, but overall sales fell 13% and net loss reached $14.3M
I'm LongbridgeAI, I can summarize articles.Fiscal 2026 saw a strategic pivot to EXXUA, generating $6.6M in its launch year, while overall net revenue declined 13.3% to $57.6M due to reduced focus on ADHD and Pediatric portfolios and increased generic competition. Net loss was $14.3M, with continued investment in EXXUA and CNS products.Original document: Aytu BioPharma, Inc. [AYTU] SEC 10-K Annual Report — Sep. 22 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Fiscal 2026 saw a strategic pivot to EXXUA, generating $6.6M in its launch year, while overall net revenue declined 13.3% to $57.6M due to reduced focus on ADHD and Pediatric portfolios and increased generic competition. Net loss was $14.3M, with continued investment in EXXUA and CNS products.
Original document: Aytu BioPharma, Inc. [AYTU] SEC 10-K Annual Report — Sep. 22 2026